Description
Saralasin TFA, formally known as [Sar¹,Ala?] Angiotensin II, is a strategic octapeptide analog designed to probe the angiotensin II receptor system. By replacing aspartic acid at position 1 with sarcosine and phenylalanine at position 8 with alanine, this analog achieves high receptor affinity, resistance to enzymatic degradation, and competitive inhibition of angiotensin II signaling—alongside modest partial agonism. This unique profile allows researchers to investigate renin-dependent (angiotensinogenic) and renovascular hypertension, offering an experimental alternative in diagnostic and mechanistic studies. Produced under GMP conditions at a purity of ?99.65%, Saralasin TFA delivers consistency and reliability in endocrine and cardiovascular research.
Product Category
Renin-Angiotensin System Probes — experimental tools for investigating angiotensinergic pathways, hypertension mechanisms, and receptor pharmacology.
Product Specifications
| Parameter | Details |
|---|---|
| Product Name | Saralasin TFA |
| Synonyms | [Sar¹,Ala?] Angiotensin II |
| CAS Number | Provided via product description |
| Purity | ?99.65% (HPLC) |
| Classification | AT? receptor antagonist with partial agonist activity |
| Mechanism | Competitive angiotensin II receptor binding (Ki ~0.32 nM for ~74% of sites) |
| Research Use | Renovascular & renin-dependent hypertension models |
| Appearance | White to off-white lyophilized powder |
| Solubility | Soluble in aqueous buffers; standard peptide solvents |
| Storage | –20 °C, protect from light and moisture |
| GMP Compliance | Yes |
Mechanism of Action & Research Applications
Saralasin TFA binds selectively to angiotensin II type 1 (AT?) receptors, competitively blocking angiotensin II-induced vasoconstriction and aldosterone secretion. Its partial agonist activity provides a distinct balance in receptor modulation. Clinically, it has been tested via infusion to differentiate renovascular hypertension—one study showed a blood pressure drop in over 80% of patients with renal artery stenosis, but fewer responses in low-renin essential hypertensive subjects. This makes it a useful tool in experimental differentiation of hypertension subtypes and renin-angiotensin system dynamics.
Side Effects (For Research Context Only)
In experimental systems, Saralasin TFA may:
Alter vascular tone and renal perfusion by modulating angiotensin II signaling
Affect renin levels due to feedback mechanisms
Introduce complexity in receptor response due to its partial agonist nature
Researchers should carefully interpret physiological outcomes and monitor for unexpected interactions in complex models.
Logistics Transportation
All orders are shipped with full transport insurance, ensuring secure and prompt delivery. We offer 100% compensation for any lost, detained, or damaged items during transit.
Disclaimer
Saralasin TFA is strictly for laboratory research use only. It is not approved for therapeutic, clinical, diagnostic, or veterinary use.


Reviews
There are no reviews yet.